Table 3.
Pro-Tumoral Activities | Therapeutic Trials | |
---|---|---|
IL-4 | Elevation in HNSCC patients (* 76, 77, 78, 79) | 81, 83 |
Protection of tumor cells (80) | ||
IL-10 | Elevation in HNSCC patients (85, 86) | |
Abrogation of anti-tumoral immunity (87) | ||
Enhancement of Treg and M2 macrophage (88) | ||
Activation of TAM (89) |
* Numbers correspond to references in the text.